Why we need a global citizens’ assembly on gene editing
By Nicole Curato and Simon Niemeyer,
The Conversation
| 09. 17. 2020
Developments in gene editing are often met with moral panic. Every new announcement raises outrage over the audacity of scientists “playing God”. The existence of mutant mosquitoesand designer babies are often framed as threats – evidence that science fiction has crossed over into real life.
There are clear dangers when the language of fear and scandal hijack public conversations on complex matters. But this doesn’t mean we should leave the discussion on genome editing – the process of altering an organism’s genetic sequence to produce favourable characteristics or remove unwanted ones – solely to scientists.
That danger was sharply underscored in 2018, when a young Chinese researcher announced he had engineered the birth of what may very well be the first genetically modified humans. “I feel proud,” he told the public, a year before he was jailed for forgery.
And so we reach an impasse. As global leaders face pressure to regulate genome editing, questions about who drives these ethical debates persist. Should leaders listen to scientists, who may be vulnerable to moral blindness, or to the...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...